Dawiyat Massoudi

Dawiyat Massoudi

Auto-generated profile, based on publicly available information

Dawiyat Massoudi

Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University, CA 94305, USA

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 February 2026 in Hepatology
Verified
Journal Article
Closed access
DMDawiyat Massoudi
Dawiyat Massoudi
ASAnkit Srivastava
Ankit Srivastava
RDRenumathy Dhanasekaran
Renumathy Dhanasekaran
Hepatocellular carcinoma (HCC) is a biologically and clinically heterogeneous cancer in which the spatial organization of the tumor microenvironment dictates progression, immune escape, and therapeutic response. Traditional genomic and transcriptomic profiling have revealed key molecular pathways, yet they do not capture the spatial relationships that govern tumor–immune–stromal interactions. Spatial omics technologies now bridge this gap, allowing molecular profiling within intact tissue architecture and revealing how cellular neighborhoods, immune barriers, and stromal niches shape tumor behavior. In this review, we summarize recent advances in technologies like spatial transcriptomics, proteomics, genomics, epigenomics, and metabolomics as applied to HCC. We discuss how these technologies have illuminated the spatial dynamics of the invasive margin, macrophage and fibroblast niches, and immune evasion, identifying both prognostic and predictive biomarkers. We further highlight how spatially resolved analyses have uncovered previously unrecognized axes of communication between cancer cells and key stromal and parenchymal populations that were not apparent from bulk or single-cell molecular analyses alone. These spatially mapped ligand–receptor networks reveal coordinated signaling circuits that define targetable mechanisms of resistance and progression within the microenvironment. Finally, we explore the translational implications where spatial signatures may guide risk stratification, treatment selection, and clinical trial design. By integrating spatial architecture with molecular function, spatial omics is transforming our understanding of liver cancer biology and paving the way for spatially informed precision oncology.

10 March 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
MTMingdian Tan
Mingdian Tan
SSSteve Schow
Steve Schow
YLYi Liu
Yi Liu
RLRobert Lum
Robert Lum
DMDawiyat Massoudi
Dawiyat Massoudi
MCMei-Sze Chua
Mei-Sze Chua
Background: Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality worldwide, underscoring the urgent need for effective therapies. The FDA-approved anthelmintic, niclosamide, is a promising repurposed drug candidate for HCC; however, its clinical application in solid tumors is hampered by poor aqueous solubility and resulting low bioavailability. Methods: We designed and screened eight novel niclosamide prodrug candidates for solubility, stability, and anti-proliferative activity in HCC cell lines. The lead compound, SSL-0024, was evaluated for pharmacokinetics and anti-tumor efficacy in an orthotopic patient-derived xenograft (PDX) model, and for cytotoxicity in patient-derived organoids (PDOs). Mechanistic studies assessed AKT–mTOR–STAT3 and other related signaling pathways. Results: The O-sulfate derivative, SSL-0024, demonstrated improved solubility and pH stability, and a sustained release of niclosamide over ∼48 h. Once-daily oral administration of SSL-0024 (100 mg/kg) achieved ∼60% tumor growth inhibition in PDX models at ∼46.8% of the niclosamide ethanolamine dose, with minimal toxicity. It also induced significantly greater cytotoxicity than sorafenib ( p<0.05 ) in the PDO. Mechanistically, SSL-0024 suppressed major oncogenic pathways including AKT–mTOR–STAT3, RAF, and Wnt/β-catenin. Conclusions: SSL-0024 overcomes key pharmacokinetic limitations of niclosamide while maintaining potent anti-tumor activity, supporting its further development as an orally bioavailable therapeutic candidate for HCC.